Dernières publications
Switching antiretrovirals in older patients
Lancet HIV. 2019 Oct;6(10):e640- e641. doi: 10.1016/S2352-3018(19)30229-2. PMID: 31578950.
Gianotti N, Castagna A.
Lire la suite
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, noninferiority trial (PROBE 2)
J Antimicrob Chemother. 2020 May 1;75(5):1332-1337. doi: 10.1093/jac/dkaa018. PMID: 32129855.
Maggiolo F, Gianotti N, Comi L, Di Filippo E, Fumagalli L, Nozza S, Galli L, Valenti D, Rizzi M, Castagna A.
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice
AIDS Rev. 2018 Apr-Jun;20(2):75-82. doi: 10.24875/AIDSRev.M18000017. PMID: 29938701.
Di Biagio A, Riccardi N, Rusconi S, Guaraldi G, Borderi M, De Luca A, Gianotti N, Lo Caputo S, Maggi P, Maserati R, Maggiolo F.
Enhancing care for people living with HIV: current and future monitoring approaches. Expert Rev Anti Infect Ther
2020 Oct 15:1-14. doi: 10.1080/14787210.2021.1823217. Epub ahead of print. PMID: 33054479.
Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A.
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy
Clin Microbiol Infect. 2020 Sep 23:S1198- 743X(20)30580-2. doi: 10.1016/j.cmi.2020.09.028. Epub ahead of print. PMID: 32979570.
Lai A, Franzetti M, Bergna A, Saladini F, Bruzzone B, Di Giambenedetto S, Di Biagio A, Lo Caputo S, Santoro MM, Maggiolo F, Parisi SG, Rusconi S, Gianotti N, Balotta C.
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients
Int J Antimicrob Agents. 2020 Mar;55(3):105893. doi: 10.1016/j.ijantimicag.2020.105893. Epub 2020 Jan 9. PMID: 31926287.
Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N.
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study
J Antimicrob Chemother. 2020 Jan 1;75(1):194-199. doi: 10.1093/jac/dkz424. PMID: 31605107.
Modica S, Redi D, Gagliardini R, Giombini E, Bezenchek A, Di Carlo D, Maggiolo F, Lombardi F, Borghetti A, Farinacci D, Callegaro A, Gismondo MR, Colafigli M, Sterrantino G, Costantini A, Ferrara SM, Rusconi S, Zazzi M, Rossetti B, De Luca A, Gianotti N.
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. PMID: 31173639.
Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group.
Evidencebased renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons
New Microbiol. 2018 Oct;41(4):247-255. PMID: 30604833.
Antinori A, Di Biagio A, Marcotullio S, Sarmati L, Andreoni M, Angarano G, Chirianni A, d'Arminio Monforte A, Di Perri G, Galli M, Gianotti N, Girardi E, Gori A, Mussini C, Perno CF, Lazzarin A.
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART
J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. PMID: 30247724.
Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group.
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen
Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13. PMID: 30009958.
Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, Lazzarin A, Castagna A.
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):417-422. doi:10.1097/QAI.0000000000001522. PMID: 28816721.
Gianotti N, Marchetti G, Antinori A, Saracino A, Gori A, Rizzardini G, Lichtner M, Bandera A, Mussini C, Girardi E, dʼArminio Monforte A, Cozzi-Lepri A.
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
PLoS One. 2017 Aug 1;12(8):e0182007. doi: 10.1371/journal.pone.0182007. PMID: 28763473; PMCID: PMC5538668.
Gianotti N, Poli A, Galli L, Franzin M, Tadini P, Galizzi N, Carbone A, Merli M, Muccini C, Oltolini C, Andolina A, Spagnuolo V, Lazzarin A, Castagna A.
Icona Foundation Study and mono-PI/r database Study Cohorts. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
PLoS One. 2017 Feb 13;12(2):e0171611. doi: 10.1371/journal.pone.0171611. PMID: 28192453; PMCID:PMC5305227.
Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M;
